José Canga Rodríguez, key account manager, Pharmaceutical and Life Sciences, EnviroChemie, and Volker Luh, CEO of EnviroDTS, describe the development, and recent successful application, of a new technology for dealing safely and effectively with the radioactive "wastewater" generated by patients who have undergone radiotherapy in nuclear medicine facilities. The BioChroma process provides what is reportedly not only a more flexible means than traditional "delay and decay" systems of dealing with this "by-product" of medical treatment, but also one that requires less plant space, affords less risk of leakage or cross-contamination, and is easier to install.